Sunovion’s Brovana Infringed Mylan Patents, Judge Rules

(Corrects third paragraph of story published July 5 to remove reference to injunction against Sunovion.)

Sunovion Pharmaceuticals Inc.’s bronchitis and emphysema drug Brovana infringed Mylan Inc. (MYL)’s patents, a judge ruled.

Sunovion also agreed not to raise any claims about the validity and enforceability of Mylan’s patents, U.S. District Judge John Koeltl said in an order dated July 1 in New York.

“The making, using, offering to sell and selling of Brovana has infringed” five Mylan patents, Koeltl said.

A unit of Canonsburg, Pennsylvania-based Mylan sued Sunovion’s predecessor company in 2007 to block the introduction of Brovana, which Mylan said infringed patents for a spray to open bronchial passages.

Sunovion, based in Marlborough, Massachusetts, is a unit of Osaka, Japan-based Dainippon Sumitomo Pharma Co.

The case is Dey v. Sepracor, 07-cv-02353, U.S. District Court, Southern District of New York (Manhattan).

To contact the reporter on this story: Don Jeffrey in New York at

To contact the editor responsible for this story: Michael Hytha at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.